ACE2 News and Research

RSS

Study develops a novel intranasal influenza virus-vectored vaccine for SARS-CoV-2

Researchers developed a novel intranasal vaccine candidate for coronavirus disease 2019 (COVID-19).

14 Apr 2023

The virological characteristics of XBB.1.16

Researchers perform extensive multiscale investigations to explore virological characteristics of the SARS-CoV-2 Omicron XBB subvariant, XBB.1.16.

12 Apr 2023

VUMC-led trial demonstrates the inefficacy of two investigational drugs for treating severe COVID-19

Despite the success of vaccines for preventing COVID-19, and of drugs for treating the disease, outcomes for severely ill patients admitted to the hospital remains poor.

11 Apr 2023

Scientists isolate two antibodies that neutralize all current SARS-CoV-2 variants of concern

Researchers found antibodies that neutralize all current SARS-CoV-2 variants.

11 Apr 2023

Study finds human surfactant protein A can inhibit SARS-CoV-2 infectivity

Researchers assess the efficacy of the human surfactant protein A against SARS-CoV-2 infectivity.

10 Apr 2023

Study highlights the potential long-term neurological effects post-COVID-19

Researchers studied the presence of the SARS-CoV-2 spike protein in the skull-meninges-brain (SMB) axis.

10 Apr 2023

Study reveals SARS-CoV-2 on hands and frequently-touched surfaces as key predictors of household transmission

A study investigating risk factors and vectors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) household transmission reveals that the presence of the virus on the hands of primary and secondary cases and on frequently-touched surfaces is associated with transmission risk. The study is published in the journal THE LANCET Microbe.

9 Apr 2023

Study explores the species-specific use of ACE2 receptors by human and animal coronaviruses

Researchers assessed the ability of spike proteins from 24 animal or human coronaviruses to utilize angiotensin-converting enzyme 2.

5 Apr 2023

The association between neutralizing antibody response breadth and long COVID symptoms

Researchers assessed neutralizing antibody responses before and after severe acute respiratory syndrome coronavirus 2 Omicron.

5 Apr 2023

Drug used to treat liver disease may decrease SARS-CoV-2 infections and reduce COVID-19 severity

SARS-CoV-2, the virus that causes COVID-19, attaches to a cellular receptor called angiotensin-converting enzyme 2 (ACE2), and activation of the farnesoid X receptor increases ACE2 expression.

5 Apr 2023

Pre-existing immunity shapes mucosal SARS-CoV-2-specific antibody responses

In a recent study, researchers assessed serological and mucosal immunity among three differing cohorts.

4 Apr 2023

Oral antiviral CD04872SC shows promise in neutralizing COVID-19 variants, offering hope for broad-spectrum treatment

Researchers discover a small molecule drug candidate that could provide immediate protection against infection with SARS-CoV-2.

4 Apr 2023

Study identifies ultra-broad SARS-CoV-2 neutralizing antibodies that target various spike epitopes

Researchers screened the circulating B lymphocyte repertoires of coronavirus disease 2019 convalescents and vaccines using multiplexed antigen panels.

3 Apr 2023

COVID-19 activates endogenous retroviruses within our genome

Researchers assess the impact of SARS-CoV-2 infection on endogenous retroviruses of the LTR69 subfamily.

28 Mar 2023

New study suggests broad neutralizing antibody could provide three years of COVID protection

In a recent article published in the journal Science Translational Medicine, researchers showed that a novel, lab-engineered monoclonal antibody (mAb), adintrevimab conferred up to 50% protection against symptomatic coronavirus disease 2019 (COVID-19). Furthermore, it demonstrated this exceptional efficacy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–naïve individuals even at titers as low as 1:30.

27 Mar 2023

Epigenome reprogramming after SARS-CoV-2 infection

Researchers performed a 3D evaluation of SARS-CoV-2 infected human cells.

27 Mar 2023

Tetravalent COVID vaccine provides broad antibody responses against SARS-CoV-2 variants in animal model

In a recent study posted to the bioRxiv* preprint server, researchers in Italy and the United States evaluated the efficacy and immunogenicity of an adjuvanted tetravalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein subunit 1 (S1) COVID-19 vaccine.

21 Mar 2023

Loss of smell following COVID-19 recovery: How long could it last?

In a recent study posted to the Preprints with The Lancet* server, researchers in China conducted a multi-center, retrospective study to gather data on the prevalence of olfactory dysfunction (OD) after three years of recovering from coronavirus disease 2019 (COVID-19).

21 Mar 2023

New SARS-CoV-2 Omicron XBB.1.5 variant has high transmissibility and infectivity, study finds

COVID-19 has caused significant global panic after its rapid emergence more than 3 years ago. Although we now have highly effective vaccines against the SARS-CoV-2 virus, which causes COVID-19, scientists continue to study emerging SARS-CoV-2 variants in order to safeguard public health and devise global preventive strategies against emerging variants.

20 Mar 2023

Research highlights the potential risk of secondary SARS-CoV-2 transmission from wild rats

In a recent study published in the journal mBio, researchers in the United States evaluated rat exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in New York City (NYC).

16 Mar 2023

ACE2 News and Research

Study develops a novel intranasal influenza virus-vectored vaccine for SARS-CoV-2

The virological characteristics of XBB.1.16

VUMC-led trial demonstrates the inefficacy of two investigational drugs for treating severe COVID-19

Scientists isolate two antibodies that neutralize all current SARS-CoV-2 variants of concern

Study finds human surfactant protein A can inhibit SARS-CoV-2 infectivity

Study highlights the potential long-term neurological effects post-COVID-19

Study reveals SARS-CoV-2 on hands and frequently-touched surfaces as key predictors of household transmission

Study explores the species-specific use of ACE2 receptors by human and animal coronaviruses

The association between neutralizing antibody response breadth and long COVID symptoms

Drug used to treat liver disease may decrease SARS-CoV-2 infections and reduce COVID-19 severity

Pre-existing immunity shapes mucosal SARS-CoV-2-specific antibody responses

Oral antiviral CD04872SC shows promise in neutralizing COVID-19 variants, offering hope for broad-spectrum treatment

Study identifies ultra-broad SARS-CoV-2 neutralizing antibodies that target various spike epitopes

COVID-19 activates endogenous retroviruses within our genome

New study suggests broad neutralizing antibody could provide three years of COVID protection

Epigenome reprogramming after SARS-CoV-2 infection

Tetravalent COVID vaccine provides broad antibody responses against SARS-CoV-2 variants in animal model

Loss of smell following COVID-19 recovery: How long could it last?

New SARS-CoV-2 Omicron XBB.1.5 variant has high transmissibility and infectivity, study finds

Research highlights the potential risk of secondary SARS-CoV-2 transmission from wild rats

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News